A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2011
11/22/2011	CA2455392C Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
11/22/2011	CA2416808C Derivatives of branched-chain lipophilic molecules and uses thereof
11/22/2011	CA2372511C Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/17/2011	WO2011143656A2 Compositions and methods of identifying tumor specific neoantigens
11/17/2011	WO2011143653A2 Recombinant hcmv and rhcmv vectors and uses thereof
11/17/2011	WO2011143646A1 Fused bicyclic kinase inhibitors
11/17/2011	WO2011143645A1 Fused bicyclic kinase inhibitors
11/17/2011	WO2011143614A1 Enhanced death receptor agonists
11/17/2011	WO2011143593A1 Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
11/17/2011	WO2011143590A1 Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
11/17/2011	WO2011143579A2 Cancer prevention and treatment methods based on dietary polyamine content
11/17/2011	WO2011143524A2 Functional, cross-linked nanostructures for tandem optical imaging and therapy
11/17/2011	WO2011143484A1 A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent
11/17/2011	WO2011143482A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
11/17/2011	WO2011143459A1 Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases
11/17/2011	WO2011143430A1 Indazole inhibitors of kinase
11/17/2011	WO2011143426A1 Compounds useful as inhibitors of atr kinase
11/17/2011	WO2011143422A1 2 -aminopyridine derivatives useful as inhibitors of atr kinase
11/17/2011	WO2011143419A1 Pyrazines useful as inhibitors of atr kinase
11/17/2011	WO2011143399A1 Compounds useful as inhibitors of atr kinase
11/17/2011	WO2011143318A2 Anti-fgfr2 antibodies
11/17/2011	WO2011143317A2 Methods for the regulation of cellular metabolism through the modulation of sirt3 activity
11/17/2011	WO2011143201A2 Ratiometric combinatorial drug delivery
11/17/2011	WO2011143160A2 Metabolic inhibitor against tumors having an idh mutation
11/17/2011	WO2011143008A1 Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
11/17/2011	WO2011142618A2 Method for preparing novel processed ginseng or an extract thereof, the usually minute ginsenoside content of which is increased
11/17/2011	WO2011142514A1 Composition containing pias3 as an active ingredient for preventing or treating cancer or immune disease
11/17/2011	WO2011142504A1 Polymeric nanospheres containing hydroxybenzyl alcohol
11/17/2011	WO2011142381A1 Benzo- or pyrido-imidazole derivative
11/17/2011	WO2011142359A1 Spiro compound and drug for activating adiponectin receptor
11/17/2011	WO2011142316A1 Nitrogen-containing heterocyclic compound having kynurenine production inhibitory activity
11/17/2011	WO2011141716A2 Pharmaceutical compounds
11/17/2011	WO2011141713A1 New bicyclic compounds as pi3-k and mtor inhibitors
11/17/2011	WO2011141458A1 Polysubstituted benzofurans and medicinal applications thereof
11/17/2011	WO2011141326A1 Substituted heterocyclyl benzyl pyrazoles, and use thereof
11/17/2011	WO2011140936A1 5,5-disubstituted-2-imino-pyrrolidine derivatives, preparation methods and pharmaceutical uses thereof
11/17/2011	WO2011140872A1 Slow release tablet of elemene anti-tumor plant medicine
11/17/2011	WO2011140828A1 Gep antibody and uses thereof
11/17/2011	WO2011127405A9 Methods and compositions for enhanced delivery of compounds
11/17/2011	WO2011115651A3 Natural plant products for control of cancer metastasis
11/17/2011	WO2011113798A3 Inhibitors of semicarabazide - sensitive amine oxidase
11/17/2011	WO2011113616A9 A nanoparticle comprising a micelle formed by an amphiphilic block- copolymer and encapsulating a gadolinium complex
11/17/2011	WO2011085276A3 Methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer
11/17/2011	WO2011085162A3 Topical transdermal dexmedetomidine compositions and methods of use thereof
11/17/2011	WO2011085039A3 Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
11/17/2011	WO2011084620A3 Particles for multiple agent delivery
11/17/2011	WO2011083999A3 Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient
11/17/2011	WO2011082271A3 Substituted triazolo-pyrimidine compounds
11/17/2011	WO2011082270A3 Substituted imidazopyridinyl-aminopyridine compounds
11/17/2011	WO2011081465A3 Pharmaceutical composition for suppression of vascularization
11/17/2011	WO2011079133A3 Compounds and methods for kinase modulation, and indications therefor
11/17/2011	WO2011076807A3 Lipids, lipid compositions, and methods of using them
11/17/2011	WO2011072290A3 Targeted dendrimer-drug conjugates
11/17/2011	WO2011071970A3 Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)
11/17/2011	WO2011071968A3 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
11/17/2011	WO2011071916A3 Sr-bi as a predictor of human female infertility and responsiveness to treatment
11/17/2011	WO2011060104A3 Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
11/17/2011	WO2011059505A3 Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
11/17/2011	WO2011044336A3 Human domain antibodies against components of the human insulin-like growth factor (igf) system
11/17/2011	WO2011038278A3 Micelle encapsulation of therapeutic agents
11/17/2011	WO2010139469A8 Antibodies against human ccn1 and uses thereof
11/17/2011	WO2010137979A8 Combination of a leucine source and an omega- 3 unsaturated fatty acid source for use in the treatment of hypercalcaemia
11/17/2011	US20110282267 Fibroblast growth factor-9 promotes hair follicle regeneration after wounding
11/17/2011	US20110282037 Antibody preparation
11/17/2011	US20110281957 Enhanced bioactive formulations of resveratrol
11/17/2011	US20110281951 Compositions and methods for treating amyloidosis
11/17/2011	US20110281950 Compositions and methods for reducing proliferation and viability of lymphoblastoid cells
11/17/2011	US20110281949 Methods and compositions for treating neuronal damage and modulating transient receptor potential channels
11/17/2011	US20110281942 Tautomycetin and Tautomycetin Analog Biosynthesis
11/17/2011	US20110281935 Combination Therapy Based on SRC and Aurora Kinase Inhibition for the Treatment of Cancer
11/17/2011	US20110281917 Substituted Benzimidazoles for the Treatment of Astrocytomas
11/17/2011	US20110281916 Migrastatin analogs and uses thereof
11/17/2011	US20110281908 Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use
11/17/2011	US20110281907 Compositions and methods for inhibition of hepatocyte growth factor receptor c-met signaling
11/17/2011	US20110281902 Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag
11/17/2011	US20110281896 Optically pure quinazoline compounds
11/17/2011	US20110281893 Compound, synthesis, composition and uses thereof
11/17/2011	US20110281888 Fused Bicyclic Kinase Inhibitors
11/17/2011	US20110281887 Compounds and method for treatment of cancer
11/17/2011	US20110281884 Fused derivatives as pi3kdelta inhibitors
11/17/2011	US20110281878 INHIBITORS OF p38
11/17/2011	US20110281872 Compositions and methods for the prevention and treatment of cancer
11/17/2011	US20110281870 Novel substituted octahydrocyclopenta[c]pyrrol-4-amines as calcium channel blockers
11/17/2011	US20110281868 Indazole inhibitors of kinase
11/17/2011	US20110281866 Heterocyclic kinase inhibitors
11/17/2011	US20110281865 Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
11/17/2011	US20110281864 Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof
11/17/2011	US20110281863 Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
11/17/2011	US20110281862 Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl
11/17/2011	US20110281859 Novel heterocyclic compounds as metap-2 inhibitors
11/17/2011	US20110281857 Pi3k/mtor kinase inhibitors
11/17/2011	US20110281856 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
11/17/2011	US20110281850 Intracellular kinase inhibitors
11/17/2011	US20110281848 Imidazole compounds having pharmaceutical activity towards the sigma receptor
11/17/2011	US20110281846 Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
11/17/2011	US20110281845 Organic compounds
11/17/2011	US20110281843 Substituted indazole derivatives active as kinase inhibitors
11/17/2011	US20110281842 Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases
11/17/2011	US20110281841 Kinase Inhibitors
11/17/2011	US20110281840 N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity

1 ... 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 ... 2211